Compare Citius Pharmaceuticals Inc (CTXR) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs ProShares UltraPro S&P500 — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while ProShares UltraPro S&P500 trades at $155.33. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | UPRO | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.82 | $155.10 |
52-Week Low | $0.48 | $89.29 |
Enterprise Value | $16.23M | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
